Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial

Patients with 70-gene signature ultralow-risk breast cancers have shown excellent survival in historic cohorts, including randomized trials. The ultralow-risk subgroup was characterized to help avoid overtreatment. We evaluated outcomes of ultralow-risk patients in the largest cohort to date. Of the...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2022-04, Vol.40 (12), p.1335-1345
Hauptverfasser:	Lopes Cardozo, Josephine M N, Drukker, Caroline A, Rutgers, Emiel J T, Schmidt, Marjanka K, Glas, Annuska M, Witteveen, Anke, Cardoso, Fatima, Piccart, Martine, Esserman, Laura J, Poncet, Coralie, van 't Veer, Laura J
Format:	Artikel
Sprache:	eng
Schlagworte:	Breast Neoplasms - drug therapy Breast Neoplasms - genetics Chemotherapy, Adjuvant Female Humans Kaplan-Meier Estimate Prognosis Proportional Hazards Models
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!